Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) EBIT: 2012-2023

Historic EBIT for RedHill Biopharma (RDHL) over the last 11 years, with Jun 2023 value amounting to $53.8 million.

  • RedHill Biopharma's EBIT rose 226.72% to $53.8 million in Q2 2023 from the same period last year, while for Jun 2023 it was -$44.0 million, marking a year-over-year increase of 70.69%. This contributed to the annual value of -$14.6 million for FY2024, which is 215.68% down from last year.
  • According to the latest figures from Q2 2023, RedHill Biopharma's EBIT is $53.8 million, which was up 284.84% from -$29.1 million recorded in Q1 2023.
  • Over the past 5 years, RedHill Biopharma's EBIT peaked at $53.8 million during Q2 2023, and registered a low of -$141.6 million during Q4 2021.
  • Its 3-year average for EBIT is -$15.1 million, with a median of $11.9 million in 2022.
  • Per our database at Business Quant, RedHill Biopharma's EBIT surged by 273.82% in 2020 and then plummeted by 421.93% in 2021.
  • Quarterly analysis of 5 years shows RedHill Biopharma's EBIT stood at $11.8 million in 2019, then surged by 273.82% to $44.0 million in 2020, then plummeted by 421.93% to -$141.6 million in 2021, then surged by 46.50% to -$75.7 million in 2022, then surged by 226.72% to $53.8 million in 2023.
  • Its EBIT stands at $53.8 million for Q2 2023, versus -$29.1 million for Q1 2023 and -$75.7 million for Q4 2022.